Press Releases

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Aug 08, 2022

Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

Jul 27, 2022

Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

Jun 24, 2022

Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company

Jun 03, 2022

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

May 26, 2022

Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

May 16, 2022

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

May 10, 2022

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

May 10, 2022

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

May 05, 2022

Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

Apr 28, 2022

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb

BMS